As the only conference focused on neoantigens, the 9th International Neoantigen Summit returns to Amsterdam as the most timely and essential gathering for the field. As your only chance this year to learn about the latest clinical data in the field and address the full translational journey – from antigen identification and validation through to biomarker strategy, clinical trial readouts and therapeutic efficacy – it’s not one to miss.

With a sharp focus on optimising translational testing, strengthening neoantigen validation and advancing novel personalised and off‑the‑shelf approaches, the conference is designed to help the industry streamline clinical trials and develop durable therapies with high immune response.

Over 3 immersive days, the summit will unite 70+ C‑level executives, directors, heads and senior scientists from leading biopharma organisations across Europe and the US. Attendees span:

• Cancer immunotherapy
• Antigen discovery
• Bioinformatics
• AI‑driven validation
• Preclinical and clinical development
• Regulatory strategy

All brought together by a shared mission to unlock the full potential of neoantigen‑targeted therapies.

With 6 new speaking companies, including Black Canyon Bio, CellVax Therapeutics, Echo Immune, Epitopea, Khosen Bio and Treos Bio, the summit convenes industry pioneers including Nykode Therapeutics, Evaxion, Geneos, and other leading innovators shaping the next generation of immunotherapies. Every session is curated for relevance, and every interaction is designed to foster meaningful collaboration.

Participants can expect critical clinical data updates, practical insights into bioinformatics and AI applications, strategies for clinical trial design and execution, and guidance on translating preclinical findings into successful clinical outcomes. More than a conference, this is the only annual checkpoint for the neoantigen community – a one‑stop platform to benchmark progress, uncover breakthroughs and build the partnerships that will drive the next wave of neoantigen‑targeted therapies forward.